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Abstract
Background Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Creatine kinase 
(CK) levels and CK-related adverse events (AEs) in tofacitinib-treated patients with UC were evaluated.
Methods Data were analyzed for three UC cohorts: Induction (phase 2 and 3 induction studies); Maintenance (phase 3 
maintenance study); Overall [patients who received tofacitinib 5 or 10 mg twice daily (b.d.) in phase 2, phase 3, or open-
label, long-term extension studies; data at November 2017]. Clinical trial data for tofacitinib-treated patients with rheumatoid 
arthritis, psoriasis, and psoriatic arthritis are presented for contextualization.
Results Week 8 mean change from baseline CK with tofacitinib 10 mg b.d. induction therapy was 91.1 U/L (95% CI, 48.1–
134.1) versus 19.2 U/L (8.5–29.9) with placebo. Among patients completing induction with 10 mg b.d. and re-randomized 
to 52 weeks of maintenance therapy, mean increases from induction baseline to the end of maintenance were 35.9 (8.1–63.7), 
90.3 (51.9–128.7), and 115.6 U/L (91.6–139.7), with placebo, 5 and 10 mg b.d., respectively. The incidence rate (unique 
patients with events per 100 patient-years) for AEs of CK elevation in the tofacitinib-treated UC Overall cohort was 6.6 versus 
2.2, 6.5, and 3.7 for tofacitinib-treated patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis, respectively. No 
serious AEs of CK elevation or AEs of myopathy occurred in UC studies.
Conclusions In patients with UC, CK elevations with tofacitinib appeared reversible and not associated with clinically sig-
nificant AEs. UC findings were consistent with tofacitinib use in other inflammatory diseases.
Trial Registration NCT00787202; NCT01465763; NCT01458951; NCT01458574; NCT01470612; NCT01262118; 
NCT01484561; NCT00147498; NCT00413660; NCT00550446; NCT00603512; NCT00687193; NCT01059864; 
NCT01164579; NCT00976599; NCT01359150; NCT02147587; NCT00960440; NCT00847613; NCT00814307; 
NCT00856544; NCT00853385; NCT01039688; NCT02187055; NCT00413699; NCT00661661; NCT01710046; 
NCT00678210; NCT01276639; NCT01309737; NCT01241591; NCT01186744; NCT01163253; NCT01877668; 
NCT01882439; NCT01976364.
Keywords Ulcerative colitis · Inflammatory bowel disease · Tofacitinib · Creatine kinase · Safety
Abbreviations
AE  Adverse event
b.d.  Twice daily
BMI  Body mass index
CI  Confidence interval
CK  Creatine kinase
CRP  C-reactive protein
HR  Hazard ratio
IR  Incidence rate
JAK  Janus kinase
MedDRA  Medical Dictionary for Regulatory Activities
OLE  Open-label, long-term extension
PsA  Psoriatic arthritis
Pso  Psoriasis
PT  Preferred term
RA  Rheumatoid arthritis
SD  Standard deviation
TNFi  Tumor necrosis factor inhibitor
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UC  Ulcerative colitis
ULN  Upper limit of normal
Introduction
Creatine and its associated enzyme creatine kinase (CK) 
play a central role in energy metabolism through the cellular 
mediation of adenosine triphosphate demand [1]. The CK-M 
cytosolic isoform of CK is expressed primarily in skeletal 
and cardiac muscle, while the CK-B cytosolic isoform is 
present in non-muscle tissues [1].
Elevations in CK may be indicative of neuromuscular 
conditions, including myositis, myopathy, and rhabdomy-
olysis [2, 3]. CK elevations may also occur due to exercise, 
endocrine disorders, and the use of prescription drugs and 
supplements [4]. CK levels may be impacted by gender, eth-
nicity, and age [2, 5–7], and accordingly, defining normal 
reference ranges for CK is challenging. A number of studies 
have demonstrated that manufacture-determined assay refer-
ence ranges categorize a substantial proportion of otherwise 
asymptomatic subjects as having elevated CK levels [8–10].
Tofacitinib is an oral, small-molecule Janus kinase 
(JAK) inhibitor for the treatment of ulcerative colitis (UC). 
Elevations in CK have been observed with JAK inhibitors, 
including tofacitinib [11–13], baricitinib [14], and upadac-
itinib [15–17], during the treatment of a range of inflam-
matory diseases. CK elevations with tofacitinib have been 
shown to be reversible with tofacitinib withdrawal [18] 
and not associated with myopathies [19]. Asymptomatic, 
drug-related CK elevations have also been observed with 
infliximab, a tumor necrosis factor inhibitor (TNFi) used 
to treat inflammatory bowel disease [20]. However, the 
origin and implications of CK elevations in patients with 
UC have not been fully explored.
In this analysis of data from tofacitinib UC clinical 
studies, we aimed to characterize changes in CK levels, 
understand the potential clinical significance of these 
changes, and evaluate possible risk factors. We also pre-
sent data from tofacitinib-treated patients with rheumatoid 
arthritis (RA), psoriasis (Pso), and psoriatic arthritis (PsA) 
to contextualize the data from the UC program.
Methods
Tofacitinib UC Studies
Data for patients with UC were obtained from an 8-week, 
double-blind, placebo-controlled phase 2 induction study 
(A3921063, NCT00787202) [21]; two identical, 8-week, 
double-blind, placebo-controlled phase 3 induction 
studies (OCTAVE Induction 1 and 2, NCT01465763 & 
NCT01458951) [12]; a 52-week, double-blind, placebo-
controlled phase 3 maintenance study (OCTAVE Sus-
tain, NCT01458574) [12]; and an ongoing, open-label, 
long-term extension (OLE) study (OCTAVE Open, 
NCT01470612; data as of November 2017 data cutoff) 
[22] (Fig. 1). Study design and results from these studies 
have been previously reported [12, 21, 22].
Fig. 1  Overview of the tofacitinib UC clinical studies and cohorts 
included in this analysis. Clinical response in OCTAVE Induction 1 
and 2 was defined as a decrease from induction study baseline total 
Mayo score of ≥ 3 points and ≥ 30%, plus a decrease in rectal bleed-
ing subscore of ≥ 1 point, or an absolute rectal bleeding subscore of 
0 or 1. Study A3921139 (OCTAVE Open) is ongoing. Remission was 
defined as a total Mayo score ≤ 2 with no individual subscore > 1, and 
a rectal bleeding subscore of 0 b.d. twice daily, N number of patients 
in each treatment group included in the cohort analysis, UC ulcerative 
colitis
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UC Analysis Cohorts
The UC analyses included patients who received treatment 
with placebo, tofacitinib 5 mg twice daily (b.d.), and tofaci-
tinib 10 mg b.d.
Data were analyzed for three UC cohorts. The Induction 
cohort included patients who received placebo or tofacitinib 
10 mg b.d. in phase 2 or phase 3 induction studies. The 
Maintenance cohort included patients who received placebo, 
tofacitinib 5 mg b.d., or tofacitinib 10 mg b.d. in OCTAVE 
Sustain. The Overall cohort included patients who received 
at least one dose of tofacitinib 5 or 10 mg b.d. in any phase 2, 
phase 3, or OLE study (OLE ongoing at the time of analysis; 
data as of November 2017 data cutoff).
For tofacitinib-treated patients with UC, mean change 
from induction study baseline CK level over time was evalu-
ated for two phases: the induction phase (patients from the 
Induction cohort) and the maintenance phase (patients in 
OCTAVE Sustain who previously received tofacitinib 10 mg 
b.d. induction therapy).
Rheumatoid Arthritis, Psoriasis, and Psoriatic 
Arthritis Cohorts
Data for tofacitinib-treated patients with RA, Pso, and PsA 
were evaluated for contextualization with the UC cohorts. 
The RA Overall cohort included tofacitinib-treated patients 
from phase 1, phase 2, phase 3, phase 3b/4, and OLE studies 
(OLE ORAL Sequel main study was completed; database 
locked at time of analysis: March 2017) [23–44]. The Pso 
Overall cohort included tofacitinib-treated patients from 
phase 2, phase 3, and OLE studies (all of which were com-
pleted as of August 2016) [11, 18, 45–48]. The PsA Overall 
cohort included tofacitinib-treated patients from phase 3 and 
OLE studies (OLE ongoing at the time of analysis; data as 
of January 2017) [13, 49, 50]. The RA, Pso, and PsA studies 
included in these analyses are summarized in Supplementary 
Table S1.
Creatine Kinase Evaluations and Analyses
In the UC OCTAVE phase 3 and OLE studies, CK levels 
were monitored periodically during treatment. CK levels 
were evaluated in OCTAVE Induction 1 and 2 at baseline 
and at weeks 2, 4, and 8; in OCTAVE Sustain at base-
line and at weeks 4, 8, 16, 24, 32, 40, and 52; and in the 
OLE at baseline and at months 1, 2, 4, 6, 9, and 12. CK 
values were not routinely monitored in the phase 2 induc-
tion study A3921063. Mean changes (and 95% confidence 
intervals [CIs]) from induction study baseline CK levels 
were calculated. In addition, Pearson correlation coef-
ficients for change from baseline CK levels and C-reac-
tive protein (CRP) were calculated for tofacitinib- and 
placebo-treated groups at weeks 4 and 8 in the UC Induc-
tion cohort, and at weeks 8, 24, and 52 in the UC Main-
tenance cohort.
In all studies, adverse events (AEs) related to CK 
elevation were defined as AEs that were reported by the 
investigator(s) and coded to the Medical Dictionary for 
Regulatory Activities (MedDRA) preferred term (PT) of 
“blood creatine phosphokinase increased.” The criteria 
for determining whether an abnormal laboratory test find-
ing should be reported as an AE were as follows: The test 
result was associated with accompanying symptoms; or 
required additional diagnostic testing or medical/surgi-
cal intervention; or resulted in a change in study dosing 
or discontinuation from the study, significant additional 
concomitant drug treatment, or other therapy; or if the 
test result was considered to be an AE by the investigator 
or sponsor.
Incidence rates (IRs; unique patients with events per 
100 patient-years) and 95% CIs for AEs of CK elevation 
were calculated using an exact Poisson method. Analysis 
of IRs excludes data from the phase 2 induction study 
A3921063 as CK levels were not routinely monitored in 
that study.
In the OCTAVE studies, any single CK eleva-
tion > 3 × the upper limit of normal (ULN) required re-
testing within 3–5 days; patients with two sequential CK 
elevations > 10 × ULN discontinued the study unless the 
causality was known not to be medically serious (e.g., 
exercise-induced). ULN for CK was approximately 170 
U/L.
Risk factors for CK elevations ≥ 3 × ULN and ≥ 5 × ULN 
in the UC Overall cohort were evaluated using a Cox 
regression model. Backward stepwise regression (factors 
were retained in the final models if significant at the 0.05 
level) was used for the evaluation. The following potential 
factors were included in the initial models: age, predomi-
nant dose of tofacitinib received (5 mg b.d. vs. 10 mg b.d., 
defined by average total daily dose < 15 mg and ≥ 15 mg, 
respectively), gender, body mass index (BMI), race, base-
line CRP, extent of UC, duration of UC, prior TNFi fail-
ure, baseline corticosteroid use, prior immunosuppressant 
use, and geographic region.
All analyses in the UC Induction and Maintenance 
cohorts were based on the study treatment received. In 
the UC Overall cohort, analyses were performed based on 
all patients who received at least one dose of tofacitinib 
5 mg b.d. or 10 mg b.d. In the RA, Pso, and PsA Overall 
cohorts, analyses were performed based on all patients 
who received at least one dose of tofacitinib.
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Results
Patients
Tofacitinib exposure, patient demographics, and CK lev-
els at baseline are presented for the UC, RA, Pso, and PsA 
cohorts in Table 1.
Tofacitinib exposure was 2051, 22 875, 8955, and 
1238 patient-years in the UC, RA, Pso, and PsA Overall 
cohorts, respectively. Median CK at baseline in the UC 
(63.0 U/L), RA (57.0 U/L), Pso (94.0 U/L), and PsA (87.0 
U/L) Overall cohorts was generally similar. Mean age 
at baseline in the UC cohorts was generally lower than 
in the RA, Pso, and PsA Overall cohorts. Mean disease 
duration in the Pso Overall cohort was greater than in 
the UC cohorts, and in the RA and PsA Overall cohorts. 
Across the Overall cohorts, the RA cohort had a generally 
higher proportion of female patients (82.6%) than the UC 
(41.3%), Pso (30.5%), and PsA (54.7%) cohorts.
Changes in CK
For tofacitinib-treated patients with UC, mean CK increased 
continually during the 8-week induction phase (Fig. 2). At 
week 8, mean change from induction study baseline CK for 
patients who received tofacitinib 10 mg b.d. was 91.1 U/L 
(95% CI, 48.1–134.1) versus 19.2 U/L (95% CI, 8.5–29.9) 
for patients who received placebo (Fig. 2). Among patients 
who completed induction treatment with tofacitinib 10 mg 
b.d., during 52 weeks of further treatment in the OCTAVE 
Sustain maintenance phase, there were a decrease in mean 
CK in patients who were switched to placebo, minimal 
changes in patients who received tofacitinib 5 mg b.d., 
and further small increases in patients who continued on 
tofacitinib 10 mg b.d. (Fig 2). Among patients completing 
induction with tofacitinib 10 mg b.d. and re-randomized to 
52 weeks of maintenance therapy during OCTAVE Sustain, 
mean change from induction study baseline CK to the end 
of the maintenance phase was 35.9 U/L (95% CI, 8.1–63.7) 
with placebo, 90.3 U/L (95% CI, 51.9–128.7) with tofaci-
tinib 5 mg b.d., and 115.6 U/L (95% CI, 91.6–139.7) with 
tofacitinib 10 mg b.d. (Fig 2).
Table 1  Demographics and baseline disease characteristics for patients in the tofacitinib UC, RA, Pso, and PsA cohorts
b.d. twice daily, CK creatine kinase, N number of evaluable patients in each treatment group or cohort, n number of patients in the specified cat-
egory, PsA psoriatic arthritis, Pso psoriasis, RA rheumatoid arthritis, SD standard deviation, UC ulcerative colitis
a N = 3660
b N = 4656
c N = 3470
d N = 759
e For the UC Induction and Overall cohorts, data from the phase 2 induction study (A3921063) are not included as CK was not routinely moni-
tored in this study. UC Induction cohort, N = 234 for placebo and N = 905 for tofacitinib 10 mg b.d.; UC Overall cohort, N = 1124
UC Induction cohort UC Maintenance cohort UC Overall 
cohort
RA Overall 
cohort
Pso Overall 
cohort
PsA Overall 
cohort
Placebo 
N = 282
Tofacitinib 
10 mg b.d. 
N = 938
Placebo 
N = 198
Tofacitinib 
5 mg b.d. 
N = 198
Tofacitinib 
10 mg b.d. 
N = 196
Tofacitinib 
all N = 1157
Tofacitinib 
all N = 7061
Tofacitinib 
all N = 3663
Tofacitinib 
all N = 783
Exposure, 
patient-
years
44.8 156.2 100.4 146.2 154.3 2050.5 22 874.5 8954.6 1237.9
Age (years), 
mean (SD)
41.4 (14.4) 41.3 (13.8) 43.4 (14.0) 41.9 (13.7) 43.0 (14.4) 41.3 (13.9) 52.1 (12.0) 44.8 (12.9) 48.7 (12.0)
Female, n 
(%)
127 (45.0) 381 (40.6) 82 (41.4) 95 (48.0) 86 (43.9) 478 (41.3) 5829 (82.6) 1117 (30.5) 428 (54.7)
Disease 
duration 
(years), 
mean (SD)
8.2 (6.8) 8.2 (7.0) 8.8 (7.5) 8.3 (7.2) 8.7 (7.0) 8.2 (7.0) 8.0 (8.1) 18.3a (11.9) 7.7 (7.2)
Median 
(range) 
CK at 
baseline,e 
U/L
61.0 (9.0–
591.0)
62.0 (7.0–
3173.0)
119.0 (7.0–
1272.0)
124.0 (20.0–
826.0)
117.0 (21.0–
1948.0)
63.0 (7.0–
3173.0)
57.0b (18.0–
1985.0)
94.0c 
(12.0–21 
382.0)
87.0d (18.0–
1283.0)
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In the UC Induction and Maintenance cohorts, correla-
tions between change from induction study baseline CK ver-
sus change from induction study baseline CRP were weak 
at all time points evaluated. (Correlation coefficients ranged 
between 0.0082 and 0.1520.)
In the RA Overall cohort, mean change from baseline CK 
was generally stable over the duration of up to 96 months; 
mean change from baseline CK at month 90 (based on 
N = 248 patients with data available at this time point) was 
88.3 U/L (95% CI, 74.6–101.9). In the Pso Overall cohort, 
mean change from baseline CK at month 57 (N = 319 at 
this time point) was 125.2 U/L (95% CI, 94.1–156.3). In 
the PsA Overall cohort, mean change from baseline CK at 
month 27 (N = 282 at this time point) was 84.7 U/L (95% CI, 
68.5–100.9) (Fig. 3).
Adverse Events of CK Elevation
In the UC Induction cohort, AEs of CK elevation (i.e., inves-
tigator-determined AEs coded to the MedDRA PT of “blood 
creatine phosphokinase increased”) occurred in 2.8% of 
patients receiving tofacitinib 10 mg b.d. (n/N = 25/905) com-
pared with 0.9% of placebo-treated patients (n/N = 2/234) 
(Table 2).
IRs for AEs of CK elevation in the UC Maintenance 
cohort are shown in Fig. 4. The IR for AEs of CK elevation 
with tofacitinib 10 mg b.d. (8.7 [95% CI, 4.6–14.8]) was 
numerically greater than with tofacitinib 5 mg b.d. (4.1 
[95% CI, 1.5–9.0]) or placebo (3.9 [95% CI, 1.1–10.1]). 
The IR for AEs of CK elevation with all tofacitinib-treated 
patients in the UC Overall cohort (6.6 [95% CI, 5.5–7.9]) 
was within the range reported with tofacitinib treatment in 
the Maintenance cohort. IRs for discrete 6-month intervals 
in the UC Overall cohort are reported in Table 3 and did 
not increase over time. The IR in the UC Overall cohort 
was higher than the IR reported in the RA (2.2 [95% CI, 
2.0–2.4]) and PsA (3.7 [95% CI, 2.7–5.0]) Overall cohorts 
and similar to that reported in the Pso Overall cohort (6.5 
[95% CI, 6.0–7.1]) (Fig. 4).
In the UC Overall cohort, 126 (11.2%) patients reported 
an AE of CK elevation; the majority of cases were mild to 
moderate in severity (as reported by the investigator), and 
there were no serious AEs of CK elevation (i.e., events 
that resulted in death, were life-threatening, resulted in a 
persistent or significant disability or incapacity, required 
patient hospitalization or prolongation of existing hos-
pitalization, or resulted in a congenital anomaly or birth 
defect). No AEs of myopathy were reported in the UC 
Fig. 2  Mean (95% CI) change from induction study baseline CK dur-
ing the tofacitinib phase 3 UC induction and maintenance phases. 
For the induction phase, data from the phase 2 induction study 
(A3921063) are not included b.d. twice daily, CI confidence interval, 
CK creatine kinase, UC ulcerative colitis
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Fig. 3  Mean (95% CI) change from baseline CK in the RA, Pso, and PsA Overall tofacitinib-treated cohorts. CI confidence interval, CK creatine 
kinase, PsA psoriatic arthritis, Pso psoriasis, RA rheumatoid arthritis
Table 2  Summary of AEs of CK elevation and laboratory parameter abnormalities in the tofacitinib UC, RA, Pso, and PsA cohorts
AEs of CK elevation were investigator-determined AEs coded to the MedDRA PT of “blood creatine phosphokinase increased”
AE adverse event, b.d. twice daily, CK creatine kinase, N number of evaluable patients in each treatment group or cohort, n number of patients 
with response in the specified category, MedDRA Medical Dictionary for Regulatory Activities, PsA psoriatic arthritis, Pso psoriasis, PT pre-
ferred term, RA rheumatoid arthritis, UC ulcerative colitis, ULN upper limit of normal
a For the UC Induction and Overall cohorts, data from the phase 2 induction study (A3921063) are not included as CK elevation was not rou-
tinely monitored in this study
b ULN was approximately 170 U/L
UC Induction cohort UC Maintenance cohort UC Overall 
cohort
RA Overall 
cohort
Pso Overall 
cohort
PsA Overall 
cohort
Placebo 
N = 234a
Tofacitinib 
10 mg b.d. 
N = 905a
Placebo 
N = 198
Tofacitinib 
5 mg b.d. 
N = 198
Tofacitinib 
10 mg b.d. 
N = 196
Tofaci-
tinib all 
N = 1124a
Tofaci-
tinib all 
N = 7061
Tofaci-
tinib all 
N = 3663
Tofacitinib 
all N = 783
AE of CK elevation
n (%) 3 (1.3) 25 (2.8) 4 (2.0) 6 (3.0) 13 (6.6) 126 (11.2) 495 (7.0) 529 (14.4) 45 (5.7)
Number leading to 
discontinuation 
from the study, 
n (%)
1 (33.3) 0 (0.0) 1 (25.0) 0 (0.0) 1 (7.7) 2 (1.6) 24 (4.8) 29 (5.5) 0 (0.0)
CK laboratory 
parameter abnor-
malities
Any single CK eleva-
tion > 3 × ULN,b 
n (%)
7 (3.0) 39 (4.3) 10 (5.1) 15 (7.6) 26 (13.3) 210 (18.7) 662 (9.4) 864 (23.6) 89 (11.4)
Two sequential 
CK eleva-
tions > 10 × ULN,b 
n (%)
0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 2 (1.0) 9 (0.8) 6 (0.1) 11 (0.3) 1 (0.1)
Digestive Diseases and Sciences 
1 3
program. One (0.1%) patient in the UC Overall cohort had 
an AE of myositis.
In the UC Overall cohort, for the 126 (11.2%) patients 
who reported an AE of CK elevation, the median time to 
event was 183 days (range 1–1579 days). In the RA Overall 
cohort, 495 (7.0%) patients had AEs of CK elevation, with 
a median time to event of 505 days (range 1–2873 days). 
In the Pso Overall cohort, 529 (14.4%) patients had AEs 
of CK elevation, with a median time to event of 266 days 
(range 1–1707 days). In the PsA Overall cohort, 45 (5.7%) 
patients with AEs of CK elevation, with a median time to 
event of 169 days (range 15–696 days).
In the tofacitinib UC clinical studies, one patient who 
received placebo during OCTAVE Sustain developed rhab-
domyolysis on day 224 of the study. The patient had received 
63 days of tofacitinib 10 mg b.d. in OCTAVE Induction 1 
and was then re-randomized to receive placebo in OCTAVE 
Sustain. The AE of rhabdomyolysis was mild in severity, did 
not require drug discontinuation, and resolved on day 250 of 
OCTAVE Sustain. The patient had CK and serum creatinine 
Fig. 4  IRs (95% CI) for AEs of 
CK elevation in the UC Mainte-
nance and Overall cohorts, and 
the RA, Pso, and PsA Overall 
cohorts. IRs for AEs of CK 
elevation in the UC Induction 
cohort are not shown due to the 
short duration (8 weeks) of the 
UC induction studies. For the 
UC Overall cohort, data from 
the phase 2 induction study 
(A3921063) are not included. 
AE adverse event, b.d. twice 
daily, CI confidence interval, 
CK creatine kinase, IR inci-
dence rate, N number of evalu-
able patients in each treatment 
group or cohort, n number of 
unique patients with events, PsA 
psoriatic arthritis, Pso psoriasis, 
RA rheumatoid arthritis, UC 
ulcerative colitis
Table 3  IRs for AEs of CK elevation in the UC Overall cohort by 6-month interval
Data from the phase 2 induction study (A3921063) are not included
AE adverse event, CI confidence interval, CK creatine kinase, IR incidence rate, N number of patients evaluable in the specified time period, n 
number of unique patients with events, UC ulcerative colitis
UC Overall cohort—Tofacitinib all
0–6 months N = 1124 >6–
12 months N = 737
>12–
18 months N = 622
>18–
24 months N = 540
>24–
30 months N = 481
>30 months N = 395
Exposure, 
patient-
years
475.4 335.0 289.3 254.2 223.3 330.1
Number of 
patients 
with AEs 
of CK 
elevation, 
n (%)
62 (5.5) 17 (2.3) 13 (2.1) 9 (1.7) 11 (2.3) 14 (3.5)
IR (95% CI) 13.0 (10.0–16.7) 5.1 (3.0–8.1) 4.5 (2.4–7.7) 3.5 (1.6–6.7) 4.9 (2.5–8.8) 4.2 (2.3–7.1)
 Digestive Diseases and Sciences
1 3
within normal range at baseline of OCTAVE Induction 1. 
On day 56 of OCTAVE Induction 1 (during treatment with 
tofacitinib 10 mg b.d.), CK was 312 U/L and serum creatinine 
was within normal range. In OCTAVE Sustain (in which the 
patient was re-randomized to receive placebo), CK decreased 
to 103 U/L on day 56 of OCTAVE Sustain and was 248 U/L on 
day 224. Serum creatinine reached a peak value of 1.5 mg/dL 
on day 224. Given the marginal increase in CK and serum cre-
atinine at the time of the event, the event did not meet the con-
ventional definition of rhabdomyolysis [51]. The elapsed time 
between the last dose of tofacitinib and onset of the AE sug-
gested this was unlikely to be related to tofacitinib treatment.
AEs of CK elevation that required discontinuation from the 
study occurred infrequently in the UC program; in the Overall 
cohort, two of the 126 patients (1.6%; both of whom were 
receiving tofacitinib 10 mg b.d. at the time of the event) were 
required to discontinue.
CK Laboratory Parameter Abnormalities
In the UC Induction and Maintenance cohorts, the propor-
tion of patients meeting criteria for monitoring (any single 
CK elevation > 3 × ULN) was numerically higher with tofaci-
tinib treatment versus placebo (Table 2). The proportion of 
patients meeting criteria for monitoring in the UC Overall 
cohort (18.7%) was greater than reported in the RA (9.4%) 
and PsA (11.4%) Overall cohorts and lower than reported in 
the Pso (23.6%) Overall cohort. The observed differences in 
age and gender across the disease cohorts in this analysis are 
potential confounders for these observations. The proportion 
of patients with two sequential CK elevations > 10 × ULN 
was ≤ 1.0% across each of the UC, RA, Pso, and PsA cohorts 
in this analysis.
Risk Factor Analysis for CK Laboratory Parameter 
Abnormalities in the UC Overall Cohort
Results of the multivariate Cox regression risk factor analyses 
for CK elevations ≥ 3 × ULN and ≥ 5 × ULN in the UC Overall 
cohort are summarized in Supplementary Table S2. Gender, 
age at onset, and geographic region were retained in the final 
model for CK elevations ≥ 3 × ULN and ≥ 5 × ULN. Addition-
ally, race was also retained in the final model for CK eleva-
tions ≥ 3 × ULN (see Supplementary Table S2). Tofacitinib 
dose was evaluated but was not identified as a significant risk 
factor for CK elevations ≥ 3 × ULN and ≥ 5 × ULN in the final 
models.
Discussion
In this analysis of data from tofacitinib UC clinical stud-
ies, tofacitinib treatment in patients with moderately to 
severely active UC appeared to be associated with revers-
ible CK elevations. Increases in CK began within the first 
two weeks of tofacitinib induction therapy and contin-
ued to week 8 of induction treatment. Continued therapy 
with tofacitinib beyond week 8 did not result in further 
clinically meaningful elevations in CK. Elevations in CK 
were not associated with clinically significant AEs such 
as rhabdomyolysis or myopathy. Few AEs of CK eleva-
tion required patients to discontinue participation in these 
studies. Multivariate Cox risk factor analysis identified 
male gender and younger age as significant risk factors 
for CK elevations ≥ 3 × ULN and ≥ 5 × ULN. Results in 
the tofacitinib UC program were generally consistent with 
observations in the tofacitinib RA, Pso, and PsA clinical 
development programs. Elucidation of the mechanism for 
the observed changes in CK requires further investigation.
Results of this integrated analysis are also consistent 
with previous analyses from the tofacitinib rheumatology 
and dermatology clinical development programs that spe-
cifically evaluated the effects of tofacitinib on CK levels 
[18, 19]. Analyses in patients with Pso demonstrated that 
increases in CK were readily reversible in patients who had 
their tofacitinib therapy withdrawn, and the degree of ele-
vation itself was not clinically significant [18]. In patients 
with RA, the effect of tofacitinib on muscle biomarkers, 
including CK, was evaluated. In this analysis, mean CK 
levels plateaued following six months of tofacitinib treat-
ment, remained within the normal reference range, and 
were not associated with clinical myopathy [19].
Our findings are also consistent with data for other 
therapies with an immunosuppressant mode of action 
used to treat inflammatory diseases, including the JAK 
inhibitors baricitinib [14], upadacitinib [15–17], and TNFi 
infliximab [20]. In RA clinical studies of baricitinib [14], 
dose-dependent increases in CK were observed within 
one week, which plateaued at 8–12 weeks. Median CK 
increase from baseline with the highest baricitinib dose 
(4 mg once daily) was 52 U/L at week 16. AEs related 
to muscle injury were infrequent, and no rhabdomyolysis 
associated with baricitinib was observed [14]. Elevated 
CK levels were among the most common AEs reported 
in clinical trials of upadacitinib in UC [15], ankylosing 
spondylitis [16], and RA [17]. In a registry study of inf-
liximab-treated patients with IBD, 30.5% had elevated CK 
levels (absolute CK > 180 U/L), but none reported persis-
tent symptoms potentially related to myopathy [20]. Other 
commonly used medications associated with increases in 
CK include antipsychotics and certain beta blockers [2], 
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as well as statins, where CK elevations 2–10 × ULN occur 
in around 5% of users [4]. As prescription drugs are a 
common cause of CK elevation, it is recommended that 
affected patients are monitored, and their medications 
reviewed [4]. For patients with elevated CK levels with 
no apparent medical explanation, current guidelines rec-
ommend that a muscle biopsy be performed for further 
investigation if one or more of the following are present: 
CK elevation ≥ 3 × ULN, myopathic electromyogram, or if 
the patient is < 25 years of age [2].
In the findings of the Cox risk factor analysis performed 
in the present study, male gender and younger age were 
associated with increased risk for elevated CK levels, 
which is consistent with previously reported observations 
of higher CK activity among men compared with women 
[2, 5, 6, 8–10] and among younger subjects (particularly 
young adult males, where the difference may be driven by 
higher muscle mass in this group) versus older subjects 
[7]. Tofacitinib dose was not identified as a significant risk 
factor in this analysis.
Although the profile of CK elevations and AEs was 
generally similar across the different disease populations 
analyzed, comparisons among populations should be inter-
preted with caution due to differences in patient population 
characteristics. In addition, differences in the age and gen-
der makeup of the patient populations—the mean age of 
the UC Overall cohort (41.3 years) was numerically lower 
than the RA (52.1), Pso (44.8), and PsA (48.7) Overall 
cohorts, and 83% of patients in the RA Overall cohort 
were female compared with 41%, 31%, and 55% in the UC, 
Pso, and PsA Overall cohorts—are of particular relevance, 
given the previously reported variation in the normal range 
of CK levels by age and gender [6, 8].
Advantages of this analysis include the large numbers 
of tofacitinib-treated patients enrolled across multiple dis-
ease populations, and the long duration of follow-up (> 22 
000 patient-years in the RA Overall cohort). In addition, 
detailed data on CK and associated AEs were collected in 
each of the UC, RA, Pso, and PsA clinical trial programs. 
However, the approach of pooling potentially heterogene-
ous patient populations for analysis in the Overall cohorts 
is a potential limitation of this study, as patients’ prior 
treatment history and permitted concomitant medications 
were different in some of the trials pooled in the Over-
all cohorts. A further limitation is that some information 
relating to AEs of CK elevation was dependent upon inter-
pretation and reporting by site investigators, and this may 
not have been reported in a uniform fashion.
In conclusion, these analyses of clinical trial data from 
patients with UC, RA, Pso, and PsA demonstrated that 
although CK elevations in tofacitinib-treated patients were 
a relatively common occurrence, they were minor, were 
reversible, and were not associated with clinically impor-
tant signs or symptoms.
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